Patent application number | Description | Published |
20100081608 | Use of Human Chorionic Gonadotropin (hCG) by Oral-Sublingual or Injectable Route as an Appetite-Suppressant Agent. - Use of Human Chorionic Gonadotropin (hCG) by oral-sublingual or injectable route for the treatment of several food disorders, as an appetite-suppressant agent, food compulsiveness as well as all of those pathologies related to hunger and/or appetite modifications, including overweight, obesity, anorexia, bulimia, emotional hyperphagia, without excluding other pathologies associated to overingestion or reduced ingestion. It also includes its use for the treatment of behavior disorders associated with an increased ingestion, either behavior disorders, neurosis, borderline personality disorders or psychosis, without excluding other psychosomatic disorders. | 04-01-2010 |
20110224140 | HUMAN CHORIONIC GONADOTROPIN (HCG) ORALLY OR FOR INJECTION FOR THE TREATMENT OF MOOD DISORDERS AND ALCOHOLISM - An HCG preparation for oral administration or for injection used either as a simple dilution or coupled to albumin or a cyclodextrin therapeutically effective in the treatment of mood disorders including (but not limited to) neurosis, irritability, depressive states and borderline states. HCG preparation as above described is also effective in the treatment of all types of alcoholism. | 09-15-2011 |
20130023465 | Use of Human Chorionic Gonadotropin (hCG) by Oral-Sublingual or Injectable Route as an Appetite-Suppressant Agent. - Use of Human Chorionic Gonadotropin (hCG) by oral-sublingual or injectable route for the treatment of several food disorders, as an appetite-suppressant agent, food compulsiveness as well as all of those pathologies related to hunger and/or appetite modifications, including overweight, obesity, anorexia, bulimia, emotional hyperphagia, without excluding other pathologies associated to overingestion or reduced ingestion. It also includes its use for the treatment of behavior disorders associated with an increased ingestion, either behavior disorders, neurosis, borderline personality disorders or psychosis, without excluding other psychosomatic disorders. | 01-24-2013 |
Patent application number | Description | Published |
20080261881 | Use of human chorionic gonadotropin (HCG) orally or for injection for the treatment of mood disorders and alcoholism - A new use of Human Chorionic Gonadotropin (HCG) diluted as previously established for the treatment of mood disorders and alcoholism. | 10-23-2008 |
20090156468 | Use of human chorionic gonadotropin oral or injectable for metabolic syndrome treatment - To be used as a therapy for patients with one or more of the following clinical symptoms or laboratory findings: high blood pressure, diabetes type 2, reactive hyperglycemia, plasmatic hypertriglyceridemia, hypercholesterolemia and gout as part of the metabolic syndrome. | 06-18-2009 |
20090176697 | Method to obtain the human Chorionic Gonadotropin (hCG)/cyclodextrin complex for oral administration, product obtained by this method and clinical and therapeutic use of the complex human Chorionic Gonadotropin (hCG)/cyclodextrin - To inform about the clinical utility human Chorionic Gonadotropin (hCG) complexed with cyclodextrins for oral administration, its utility in different pathologies and method for obtaining it. | 07-09-2009 |
20110178012 | USE OF HUMAN CHORIONIC GONADOTROPIN ORALLY FOR THE TREATMENT OF OVERWEIGHT (OBESITY) ASSOCIATED WITH HIGH BLOOD TENSION, NON-INSULIN-DEPENDANT DIABETES, HYPERCHOLESTEROLEMIA, DYSLIPIDEMIAS AND LIPODYSTROPHY. - Human chorionic gonadotropin administered by intramuscular route is traditionally used for the treatment of sterility and cryptorchidism. After numerous tests performed, a compound to be administered orally—sublingual—has been developed with such drug to treat patients suffering from overweight associated with high blood tension, non-insulin-dependant diabetes, hypercholesterolemia, dyslipidemias and lipodystrophy. It was determined that hCG acts satisfactorily upon high blood tension, non-insulin-dependant diabetes, hypercholesterolemia, dyslipidemias and lipodystrophy. | 07-21-2011 |